Mindmed to present at upcoming april medical conferences

New york--(business wire)---- $mnmd--mind medicine (mindmed) inc. (nasdaq: mnmd), (cboe canada: mmed), (the “company” or “mindmed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that covid has had on the epidemiology of generalized anxiety disorder at two upcoming medical conferences: european psychiatric association (epa) 2024 congress title: prevalence of generalized anx.
MNMD Ratings Summary
MNMD Quant Ranking